Very few active ingredients of CBD are absorbed into the body, thanks to liver enzymes, which destroy over 80% of the essential components. However, LPT can enable increased bioavailability, targeted towards a specific organ or body part, with precise time and dosage control.
A study carried out on mice by the Hebrew University of Jerusalem, in Israel on Innocan's CBD-loaded LPT showed a “prolonged release” of CBD into the blood for “at least three weeks after one administration.”
The study led by Dr Ahuva Cern, a senior researcher in Professor Berenholz’s lab in the Hebrew University of Jerusalem, on over 35 mice found “significant amounts” of CBD in the mice's blood “21 days after they were injected with a single injection of liposomal CBD using Innocan's CBD loaded LPT,” said the company.
The results are “substantial” when compared with smoking or oral administration of CBD, in which CBD was found in the blood of the mice only for 36 hours after one administration. “These results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations,” said the company.
InnoCan Pharma’s subsidiary Innocan Israel has struck a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem for the design, preparation, characterization and evaluation of hydrogels containing CBD or other cannabinoids loaded liposomes.
The R&D is led by Professor Chezy Barenholz, head of the membrane and liposome research department at the Hebrew University, which invented over 55 patent families, two of which underlie Doxil — an FDA approved drug for breast cancer. The company believes this unique technology platform may be used for several indications such as epilepsy, pain relief, inflammation and central nervous system disorders.
Professor Chezy Berenholz said: "The results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone. This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time, which may also lead to improved patient's compliance.”
Meanwhile, Innocan CEO Iris Bincovich noted that the company is advancing a revolutionary platform for more efficient CBD delivery and a variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions.
“This has the potential to address indication such as epilepsy,” added Bincovich.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive